SpectRx, Inc. Stockholders Elect Directors; Approve Charter Amendments

SpectRx, Inc. (Pink Sheets: SPRX) today announced the election of its board of directors and approval of additional items that required stockholder authorization. The newly elected board of directors is: Ronald W. Hart, Ph.D, John E. Imhoff, M.D., Michael C. James, William E. Zachary, Jr. and Mark L. Faupel, Ph.D. Dr. Faupel also serves as the company’s chief executive officer and president. "I am pleased that the stockholders of SpectRx have shown their confidence in the board and management of the company and its new focus on non-invasive cervical cancer detection,” said Dr. Faupel. "We will aggressively pursue our plan to complete the reorganization of the company and move our products to market.” Additional items approved by the stockholders are: to change the name of the Company to Guided Therapeutics, Inc.; to increase the number of authorized shares of common stock to a total of 100,000,000 shares; to increase by 4,000,000 the number of shares available for grant under SpectRx's 1995 Stock Plan, and; a reverse stock split in a ratio ranging from one-for-two to one-for-ten of all issued and outstanding shares of common stock, the final ratio to be determined within the sole discretion of the Board of Directors. About SpectRx SpectRx, Inc. (Pink Sheets: SPRX) is developing a rapid and painless test for the early detection of disease that leads to cervical cancer. The technology is designed to quickly eliminate false positive Pap and HPV results and discover cervical disease missed by existing tests. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are known immediately. For more information, visit SpectRx’s web sites at www.spectrx.com and www.guidedtherapeutics.com. The SpectRx Non-invasive Cervical Cancer Detection Device is an investigational device and is limited by federal law to investigational use. "Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from SpectRx’s actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors” in SpectRx’s reports filed with the SEC, including SpectRx’s Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 and subsequent quarterly reports.